Equities Analysts Offer Predictions for NAMS FY2027 Earnings

Key Points

• HC Wainwright lowered NewAmsterdam Pharma’s FY2027 EPS forecast to $2.15 from $2.36, while projecting EPS of $3.66 in FY2028, $6.84 in FY2029 and $7.68 in FY2030.
• Analyst sentiment remains broadly positive, with the stock carrying a consensus “Moderate Buy” rating and a $49.33 average price target; recent targets range from $45 to $58.
• NewAmsterdam reported a quarterly loss of $0.52 per share, missing estimates by $0.04, although revenue of $3.70 million exceeded expectations. Shares opened at $27.67, down from their 52-week high of $42.21.

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report) - Equities research analysts at HC Wainwright lowered their FY2027 earnings per share (EPS) estimates for shares of NewAmsterdam Pharma in a research note issued to investors on Thursday, August 6th. HC Wainwright analyst L. Egana-Gorrono now anticipates that the company will post earnings per share of $2.15 for the year, down from their prior forecast of $2.36. The consensus estimate for NewAmsterdam Pharma's current full-year earnings is ($1.78) per share. HC Wainwright also issued estimates for NewAmsterdam Pharma's FY2028 earnings at $3.66 EPS, FY2029 earnings at $6.84 EPS and FY2030 earnings at $7.68 EPS.

Other research analysts also recently issued research reports about the stock. Royal Bank Of Canada decreased their price target on shares of NewAmsterdam Pharma from $51.00 to $50.00 and set an "outperform" rating for the company in a research note on Thursday. Jefferies Financial Group reissued a "buy" rating and issued a $45.00 price objective on shares of NewAmsterdam Pharma in a research report on Monday, July 20th. Wall Street Zen upgraded shares of NewAmsterdam Pharma from a "sell" rating to a "hold" rating in a report on Saturday, May 9th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of NewAmsterdam Pharma in a research report on Friday, July 17th. Finally, BMO Capital Markets initiated coverage on shares of NewAmsterdam Pharma in a research note on Monday, July 20th. They set an "outperform" rating and a $58.00 target price for the company. Two equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, NewAmsterdam Pharma currently has a consensus rating of "Moderate Buy" and a consensus target price of $49.33.

NewAmsterdam Pharma Stock Performance

NAMS stock opened at $27.67 on Friday. The company's 50 day moving average price is $31.49 and its 200 day moving average price is $32.53. The firm has a market capitalization of $3.23 billion, a price-to-earnings ratio of -12.81 and a beta of 0.10. NewAmsterdam Pharma has a fifty-two week low of $22.26 and a fifty-two week high of $42.21.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.04). NewAmsterdam Pharma had a negative net margin of 3,644.21% and a negative return on equity of 34.05%. The company had revenue of $3.70 million during the quarter, compared to analysts' expectations of $2.83 million.

Insider Buying and Selling at NewAmsterdam Pharma

In related news, CAO Louise Frederika Kooij sold 105,000 shares of the business's stock in a transaction that occurred on Monday, July 20th. The stock was sold at an average price of $30.34, for a total transaction of $3,185,700.00. Following the completion of the sale, the chief accounting officer owned 24,353 shares in the company, valued at $738,870.02. The trade was a 81.17% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Over the last quarter, insiders sold 210,000 shares of company stock worth $6,713,550. 12.74% of the stock is currently owned by company insiders.

Institutional Trading of NewAmsterdam Pharma

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in NAMS. Duquesne Family Office LLC grew its holdings in shares of NewAmsterdam Pharma by 131.2% during the third quarter. Duquesne Family Office LLC now owns 1,923,700 shares of the company's stock worth $54,710,000 after purchasing an additional 1,091,525 shares during the last quarter. Castle Hook Partners LP purchased a new stake in shares of NewAmsterdam Pharma in the 4th quarter valued at about $38,062,000. Adage Capital Partners GP L.L.C. lifted its holdings in shares of NewAmsterdam Pharma by 54.5% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 3,013,009 shares of the company's stock valued at $54,566,000 after purchasing an additional 1,062,359 shares during the last quarter. Goldman Sachs Group Inc. boosted its position in shares of NewAmsterdam Pharma by 96.0% in the 4th quarter. Goldman Sachs Group Inc. now owns 1,725,662 shares of the company's stock valued at $60,536,000 after purchasing an additional 845,110 shares during the period. Finally, Wellington Management Group LLP boosted its position in shares of NewAmsterdam Pharma by 21.0% in the 3rd quarter. Wellington Management Group LLP now owns 4,020,126 shares of the company's stock valued at $114,332,000 after purchasing an additional 697,129 shares during the period. Institutional investors and hedge funds own 89.89% of the company's stock.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source